Who we are:
The Critical Path for Sickle Cell Disease (CP-SCD) Consortium is a public- private partnership that includes diverse stakeholders in the sickle cell disease (SCD) field, including industry, academia and regulatory agencies.
What we do:
CP-SCD’s mission is to accelerate and de-risk medical product development to benefit individuals living with this disease. CP-SCD interfaces with C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform, the Quantitative Medicine Program, the Patient-Reported Outcome Consortium, regulatory science and others to accomplish its mission.
Pre-competitive engagement facilitates alignment of the SCD field and regulatory authorities to identify and prioritize solutions for unmet needs in medical product development for sickle cell disease.